Serological diagnosis of liver metastasis in patients with breast cancer

Cancer Biology and Medicine

Volumn 9, Issue 1, 2012, Pages 57-62

  Cao, Rui ^a   Wang, Li Ping ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast neoplasms; Gamma glutamyltransferase; Liver; Neoplasm metastasis; Oxidoreductases

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); DIAGNOSTIC ACCURACY; FEMALE; HOSPITAL PATIENT; HUMAN; KOLMOGOROV SMIRNOV TEST; LIVER METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

EID: 84874623441     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.2095-3941.2012.01.011     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Er O, Frye DK, Kau SW, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 2008; 14: 62-68.
3. Jardines L, Callans LS, Torosian MH. Recurrent breast cancer: Presentation, diagnosis, and treatment. Semin Oncol 1993; 20: 538-547.
4. Atalay G, Biganzoli L, Renard F, et al. Clinical outcome of breast cancer patients with liver metastases alone in the anthracyclinetaxane era: A retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003; 39: 2439-2449.
5. Hoe AL, Royle GT, Taylor I. Breast liver metastases--incidence, diagnosis and outcome. J R Soc Med 1991; 84: 714-716.
6. Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003; 8: 241-251.
7. Saad RS, Luckasevic TM, Noga CM, et al. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fineneedle aspiration cytology. Diagn Cytopathol 2004; 30: 1-6.
8. Pelloni A, Gertsch P. Risks and consequences of tumor seeding after percutaneous fine needle biopsy four diagnosis of hepatocellular carcinoma. Schweiz Med Wochenschr 2000; 130: 871-877.
9. De Santis M, Alborino S. Hemobilia due to a portobiliary fistula as a complication of a fine-needle liver biopsy. Radiol Med 1996; 91: 482-485.
10. Clevert DA, Jung EM, Stock KF, Weckbach S, Feuerbach S, Reiser M, Jung F. Evaluation of malignant liver tumors: Biphasic MSCT versus quantitative contrast harmonic imaging ultrasound. Z Gastroenterol 2009; 47: 1195-1202.
11. Berman CG, Clark RA. Diagnostic imaging in cancer. Prim Care 1992; 19: 677-713.
12. Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 2003; 89: 284-290.
13. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000; 26: 91-102.
14. Tampellini M, Berruti A, Gerbino A, et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997; 75: 698-702.
15. O'Reilly SM, Richards MA, Rubens RD. Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer 1990; 26: 574-577.
16. Sahin AA. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol 2000; 7: 158-166.
17. Schmidt M, Gehrmann M, Hengstler JG, et al. New prognostic and predictive factors in breast cancer. Minerva Ginecol 2010; 62: 599-611.
18. Corrao G. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors Breast Cancer Res Treat 2001; 67: 189.
19. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001; 28: 27-32.
20. Molina R, Zanon G, Filella X, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36: 41-48.
21. Hayes DF, Zurawski VR Jr, et al. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986; 4: 1542-1550.
22. Duffy MJ, Evoy D, McDermott EW. CA 15-3: Uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010; 411: 1869-1874.
23. Valenzuela P, Mateos S, Tello E, et al. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur J Gynaecol Oncol 2003; 24: 60-62.
24. Cañizares F, Sola J, Pérez M, et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: A multivariate analysis. Tumour Biol 2001; 22: 273-281.
25. Wu XZ, Ma F, Wang XL. Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol 2010; 16: 4084-4088.
26. Munjal D, Chawla PL, Lokich JJ, et al. Carcinoembryonic antigen and phosphohexose isomerase, gammaglutamyl transpeptidase and lactate dehydorgenase levels in patients with and without liver metastases. Cancer 1976; 37: 1800-1807.
27. Millán JL, Fishman WH. Biology of human alkaline phosphatases with special reference to cancer. Crit Rev Clin Lab Sci 1995; 32: 1-39.
28. Rotenberg Z, Weinberger I, Davidson E, et al. Lactate dehydrogenase isoenzyme patterns in serum of patients with metastatic liver disease. Clin Chem 1989; 35: 871-873.
29. Baur M, Schlappack O, Havelec L, et al. Prognostic significance of liver metastases as first site of generalisation in patients with breast cancer--a retrospective analysis. Acta Med Austriaca 2001; 28: 135-140.